drugset / Trial / NCT02338245
Study of ASLAN001 in Combination With Capecitabine in MBC That Has Failed on Prior Trastuzumab
RandomizedParallel-groupOpen-labelTreatment
Summary
This is an open-label, randomized, parallel group Phase 2A/2B study to evaluate the clinical activity of ASLAN001 in combination with capecitabine compared with lapatinib in combination with capecitabine in patients with HER2 positive metastatic breast cancer that has failed on prior trastuzumab therapy.
Timeline
- Start
- 2014-12-29
- Primary completion
- 2016-05-19
- Completion
- 2016-08-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Capecitabine | Small molecule | 1000 mg/kg | Oral |
| Subject | Capecitabine | Small molecule | 1000 mg/m2 | Oral |
| Comparator | Lapatinib | Small molecule | 1250 mg | Oral |
| Subject | Varlitinib | Small molecule | 400 mg | Oral |